Sutro Biopharma (STRO) Other Non-Current Liabilities (2016 - 2026)

Sutro Biopharma has reported Other Non-Current Liabilities for 10 years, with the latest figure at $1.7 million in Q4 2025.

• Quarterly Other Non-Current Liabilities changed 0.0% year-over-year to $1.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.7 million (changed 0.0% YoY) and the FY2025 annual result came in at $1.7 million, changed 0.0% from the prior year.
• Other Non-Current Liabilities held at $1.7 million in Q4 2025 per STRO's latest filing, from $1.7 million in the prior quarter.
• Over five years, Other Non-Current Liabilities peaked at $1.7 million in Q4 2023 and troughed at $119000.0 in Q4 2022.
• A 5-year average of $1.1 million and a median of $1.7 million in 2023 frame the typical range for Other Non-Current Liabilities.
• The sharpest annual moves came in 2022 and 2023: Other Non-Current Liabilities tumbled 91.16% in 2022, then jumped 1323.53% in 2023.
• Over 5 years, Other Non-Current Liabilities stood at $146000.0 in 2021, then fell by 18.49% to $119000.0 in 2022, then surged by 1323.53% to $1.7 million in 2023, then changed by 0.0% to $1.7 million in 2024, then changed by 0.0% to $1.7 million in 2025.
• According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $1.7 million, $1.7 million, and $1.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.